# Preserved Menstruation After Chemoradiotherapy in Stage IIIC1 Cervical Cancer: A Unique Case

**Authors:** Georgia Ilia, Athanasios Thomopoulos, Dimitrios Chronas

PMC · DOI: 10.3390/jcm15041550 · 2026-02-15

## TL;DR

A young woman with advanced cervical cancer retained her menstrual cycle after treatment, challenging assumptions about fertility loss in such cases.

## Contribution

This is the first reported case of preserved menstruation after ovarian transposition and chemoradiotherapy in FIGO stage IIIC1 cervical cancer.

## Key findings

- Menstruation resumed seven months after treatment completion with regular cycles.
- Ovarian reserve was partially preserved, as indicated by hormonal assessment and endometrial thickness.
- Low ovarian radiation exposure (<2 Gy) may have contributed to preserved reproductive function.

## Abstract

Background: In young women with cervical cancer, fertility preservation remains challenging, as chemoradiotherapy can severely compromise ovarian reserve and endometrial function. Although ovarian transposition prior to pelvic radiotherapy is well established in early-stage disease, evidence regarding ovarian and endometrial outcomes in advanced stages, particularly in the International Federation of Gynecology and Obstetrics (FIGO) stage IIIC1, remains extremely limited. Case Presentation: We report the case of a 31-year-old nulliparous woman with a histopathologically confirmed FIGO IIIC1 cervical squamous cell carcinoma who underwent a lateral ovarian transposition followed by external beam radiotherapy (ERBT) of the pelvis and interstitial high-dose-rate (HDR) brachytherapy combined with five cycles of cisplatin-based chemotherapy. A detailed dosimetrical analysis demonstrated extremely low ovarian radiation exposure (mean dose < 2 Gy bilaterally). Menstruation resumed seven months after treatment completion, with regular 27–30-day cycles. A day-3 hormonal assessment showed a partial preservation of the ovarian reserve, and the pelvic ultrasound confirmed a thickness of 7 mm in the proliferative phase, implying endometrial function despite full-dose pelvic irradiation. Conclusions: To our knowledge, this is a very unique case of preserved menstruation after ovarian transposition and chemoradiotherapy for FIGO IIIC1 cervical carcinoma. This case challenges the conventional assumptions regarding ovarian failure and endometrial destruction in such cases, suggesting that reproductive potential may occasionally be retained. Although fertility remains a challenging point, this case report underscores the need for individualized counseling and prospective oncofertility research.

## Linked entities

- **Chemicals:** cisplatin (PubChem CID 5460033)
- **Diseases:** cervical cancer (MONDO:0002974), cervical squamous cell carcinoma (MONDO:0006143)

## Full-text entities

- **Genes:** AMH (anti-Mullerian hormone) [NCBI Gene 268] {aka MIF, MIS}, MUC16 (mucin 16, cell surface associated) [NCBI Gene 94025] {aka CA125}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** atrophy (MESH:D001284), adnexal disease (MESH:D000291), adenocarcinoma (MESH:D000230), cancer (MESH:D009369), Cervical Cancer (MESH:D002583), ovarian failure (MESH:C564499), hypertension (MESH:D006973), vaginal bleeding (MESH:D014592), metastases (MESH:D009362), fibrosis (MESH:D005355), para-aortic disease (MESH:D001018), premature ovarian insufficiency (MESH:D016649), injury to (MESH:D014947), cervical malignancy (MESH:D002575), damage (MESH:D020263), SCC (MESH:D002294), OT (MESH:D010049), fistula (MESH:D005402), bowel herniation (MESH:D004677), stage IIIC1 (MESH:D062706), ischemia (MESH:D007511), ovarian cancer (MESH:D010051), thromboembolic complications (MESH:D013923), bleeding (MESH:D006470), FIGO (MESH:D005831), squamous cervical carcinoma (MESH:D065309), endometrial damage (MESH:D014591)
- **Chemicals:** paclitaxel (MESH:D017239), E2 (MESH:D004958), OT (-), Cisplatin (MESH:D002945), platinum (MESH:D010984), Bevacizumab (MESH:D000068258), Pap (MESH:D010724)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human papillomavirus (species) [taxon 10566], Human papillomavirus 16 (serotype) [taxon 333760]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941671/full.md

---
Source: https://tomesphere.com/paper/PMC12941671